NRIX
NASD Nurix Therapeutics, Inc.$26.10 ↑ +0.00 (+0.00%) Trading Up from the previous close of $26.10, $0.24 below the day’s high of $26.34
- YTD change
- +37.59%
- vs 20-day SMA
- +11.39%
- vs 200-day SMA
- +31.67%
Price ranges
Price & Performance
+9.06 (+53.17%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 50.2% away from all-time highs of $52.38
- NRIX is up 38% since the beginning of the year
- NRIX is up 151% over the past 12 months
- NRIX is up 3% over the past 1 month
- 16% of all NRIX investors are betting against NRIX
NRIX reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +151.2%.
- Previous minute
- +$0.00
- Last hour
- -$0.15
- Last 5 days
- +17.78%
- vs 8-day SMA
- +11.77%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
